Page last updated: 2024-12-08

oncocalyxone a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oncocalyxone A: a 1,4-anthracenedione isolated from Auxemma oncocalyx (Boraginaceae) that has been shown to be cytotoxic to tumor cells in vitro [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Oncocalyxgenus[no description available]LoranthaceaeThe showy mistletoe plant family of the order Santalales, subclass Rosidae, class Magnoliopsida. This includes parasitic tropical plants with haustoria connecting to the hosts. The leaves are opposite and thick. The flowers (4-7) have both calyx and corolla. The fruit is a berry with one seed.[MeSH]

Cross-References

ID SourceID
PubMed CID404386
CHEMBL ID1975567
MeSH IDM0363273

Synonyms (7)

Synonym
nsc720597
NCI60_041320
rel-8.alpha.hydroxy-5-hydroxymethyl-8a.beta.-methyl-2-methoxy-7,8a,9-tetrahydro-1,4-anthracenedione
nsc-720597
oncocalyxone a
(5r,10as)-5-hydroxy-8-(hydroxymethyl)-3-methoxy-10a-methyl-6,10-dihydro-5h-anthracene-1,4-dione
CHEMBL1975567

Research Excerpts

Overview

Oncocalyxone A (oncoA) is a quinone extracted from the Cordia oncocalyX plant.

ExcerptReferenceRelevance
"Oncocalyxone A (oncoA) is a quinone extracted from the Cordia oncocalyx plant. "( Does Oncocalyxone A (oncoA) have intrinsic fluorescence?
Cabral Filho, PE; Cavalcanti, IDL; Fontes, A; Lira Nogueira, MCB; Pessoa, ODL; Santos Magalhães, NS; Souto, FO; Ximenes, RM, 2022
)
2.68

Effects

Oncocalyxone A has many pharmaceutical uses such as: antitumor, analgesic, antioxidant and causative of inhibition of platelet activation. OncoA has a concentration-dependent anti-platelet activity.

ExcerptReferenceRelevance
"Oncocalyxone A (OncoA) has a concentration-dependent anti-platelet activity. "( Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Chudzinski-Tavassi, AM; de Lemos, TL; de Sousa, CM; do Nascimento, NR; Ferreira, MA; Pessoa, OD; Schattner, M; Ventura, JS, 2008
)
3.23
"Oncocalyxone A (Onco A) has many pharmaceutical uses such as: antitumor, analgesic, antioxidant and causative of inhibition of platelet activation."( Study of molecular structure, vibrational, electronic and NMR spectra of oncocalyxone A using DFT and quantum chemical calculations.
Ayala, AP; Fechine, PB; Honorato, SB; Joshi, BD; Pessoa, OD; Srivastava, A; Tandon, P, 2013
)
1.34
"Oncocalyxone A (OncoA) has a concentration-dependent anti-platelet activity. "( Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Chudzinski-Tavassi, AM; de Lemos, TL; de Sousa, CM; do Nascimento, NR; Ferreira, MA; Pessoa, OD; Schattner, M; Ventura, JS, 2008
)
3.23
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's4 (30.77)24.3611
2020's5 (38.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]